Part 8/8:

• Ongoing platform development, with new features being added to the Galaxy open-source bioinformatics platform, including hypothesis generation and gene annotation services.

• Plans to roll out a beta product for select testers in the second quarter of 2025.

These updates highlight Ru Bio's continued efforts to leverage AI and AGI technologies to advance health and longevity research and solutions.